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Abstract
Background: The multiplexing becomes the major limitation of the next-generation sequencing (NGS) in
application to low complexity samples. Physical space segregation allows limited multiplexing, while the existing
barcode approach only permits simultaneously analysis of up to several dozen samples.
Results: Here we introduce pair-barcode sequencing (PBS), an economic and flexible barcoding technique that
permits parallel analysis of large-scale multiplexed samples. In two pilot runs using SOLiD sequencer (Applied
Biosystems Inc.), 32 independent pair-barcoded miRNA libraries were simultaneously discovered by the
combination of 4 unique forward barcodes and 8 unique reverse barcodes. Over 174,000,000 reads were generated
and about 64% of them are assigned to both of the barcodes. After mapping all reads to pre-miRNAs in miRBase,
different miRNA expression patterns are captured from the two clinical groups. The strong correlation using
different barcode pairs and the high consistency of miRNA expression in two independent runs demonstrates that
PBS approach is valid.
Conclusions: By employing PBS approach in NGS, large-scale multiplexed pooled samples could be practically
analyzed in parallel so that high-throughput sequencing economically meets the requirements of samples which
are low sequencing throughput demand.
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Background
Next-generation sequencing (NGS) technologies which
are widely employed in life science research, are trans-
forming the biology[1]. In one slide, NGS technologies
can generate over one billion DNA sequences now, 1.4
billion by SOLiD 5500 × l (Applied Biosystems Inc.) and
1 billion by Hiseq 2000 (Illumina Inc.). This capacity
has increased by dozens of times in the past several
years and continuously increases in a rapid speed. The
ever increasing reads throughput permits to analyze
high complex samples [2,3]. However, for the studies of
lower complex samples, such as miRNA discovery, NGS
technologies turn to be inefficient and uneconomic.
This situation will be aggravated in the future by the
ever increasing reads throughput.
In order to relieve the mismatch between the high
throughput of NGS technologies and the low through-
put requirement of the low complex samples, most NGS
technologies provide physically segregated sequencing
mediums. But the physical segregation allows accommo-
dation of limited independent samples, and obscures
available sequencing space in some NGS technologies
[4]. Barcodes, the unique DNA sequence identifiers, his-
torically used in several experimental contexts, are first
introduced to the NGS technologies by Meyer et al and
Parameswaran et al[4,5] in the pyrosequencing platform.
This approach is widely employed to analyze pooled
lower complex samples [5-12]. The barcode approach
allows the simultaneous analysis of infinite number of
samples in theory, but in applications, the researchers
analyze at most dozens of samples in parallel[6]. Along
with the increasing sample number, the variety of sam-
ple-specific primers or adaptors increases at the same
speed and this approach becomes less practicable when
the sample number becomes large. We have developed
a method called pair-barcode sequencing (PBS) for the
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any medium, provided the original work is properly cited.practical parallel analysis of large-scale multiplexed sam-
ples. Although a pair of barcodes was designed to
enhance the reliability of experiment[4] or to allow the
sequencing starting from both ends of the libraries[10],
we have not found any study which assign a pair of bar-
codes in NGS to improve the practicability and paralle-
lism in analyzing large-scale multiplexed samples.
MicroRNAs (miRNAs) are an evolutionarily conserved
class of small, approximately 22-nucleotide (nt) non-
coding RNAs that regulate global gene expression pat-
terns[13,14] and play an important role in the develop-
ment and progression of cancer[15]. Breast cancer, the
second-leading cause of cancer related deaths in
women, is expected to account for 26% of new cancer
diagnoses in 2008[16]. Aberrant expression of miRNAs
in human breast cancers were first reported by Iorio et
al in 2005[17]. A large number of miRNAs were demon-
strated to be associated with breast cancer in the recent
years [17-29].
In our method, a pair of molecular barcodes of 6nt in
length is designed at the two sides of the target
sequences and is introduced to the libraries by adaptor
ligation and PCR. We demonstrate the power of PBS by
sequencing a pool of 32 human miRNA libraries on the
SOLiD V2 platform (Applied Biosystems Inc.). 26 of
these libraries were derived from human breast cancer
cancerous tissues (BC) and 6 were derived from human
breast noncancerous tissues (BO). Four unique forward
barcodes (F-barcode) and eight unique reverse barcodes
(R-barcode) were used to code the 32 samples. Addi-
tionally, we evaluate the correlation of different barcode
pairs by performing technical replicates of the same
sample with 16 different barcode pairs, and verified the
reproducibility of the method by operating two indepen-
dent sequencing run of the same pool of samples. After
decoding and mapping, about 64% of the reads mapped
to both of the two barcodes uniquely and 15.3% of
decoded reads were identified to non coding RNAs on
average. The peak read length of the reads recognized
as miRNAs located at 21-22nt, indicating that the
mature miRNAs were enriched in the samples and well
sequenced. A total of 22 miRNAs were differentially
expressed between the BC libraries and BO libraries. To
the best of our knowledge, this is the first study to dis-
cover miRNAs from large-scale multiplexed samples
using a pair of barcodes in NGS.
Results
Outline of PBS and design of barcodes
In order to substantially enhance the scope and capacity
of multiplexed high-throughput sequencing, a pair of
barcodes for 6nt each was designed in two sides of miR-
NAs. The F-barcodes were devised at the 5’ end of the
F-adaptors, and were introduced to the libraries by
ligating the F-adaptors to miRNAs (Figure 1A). The R-
barcodes were designed in the overhangs of the R-pri-
mers, and were led to the libraries by PCR reactions
(Figure 1C). Each sample was coded by the combination
of a unique F-barcode and a unique R-barcode. In order
to carry out ePCR reactions, the left and right ePCR pri-
mers were designed in the pair-barcoded library. The
left ePCR primers (reverse complementary sequence)
were located at the 3’ end of F-adaptors and the right
ePCR primers were designed in the overhangs of the R-
primers, at the 5’ end the R-barcodes. Two sequencing
primers, sequencing primer A and sequencing primer B,
were used to execute the sequencing reactions. The
sequencing primer A is in charge of sequencing the F-
barcodes and miRNAs while the sequencing primer B is
responsible for sequencing R-barcodes. The sequence of
each reads was obtained after sequencing runs and is
made up of 3 parts, the F-barcode, the R-barcode and
the target sequence. By decoding the F-barcodes and R-
barcodes consequently, the target sequences were
ascribed to the different samples.
As one mismatch is tolerated in barcode mapping, it is
impossible to get uniquely mapped reads if all permuta-
tions of 6 nucleotides are allowed to be barcodes. In
order to get uniquely mapped reads, each barcode
should be different with each other in at least three
positions. Moreover, because the mapping of SOLiD
reads is operated in the color space, the barcodes are
designed to be different with each other in at least two
positions in the color space, not in the nucleotide space.
Pair-barcode decoding
After the sequencing reactions, 89175789 barcoded
sequences were obtained in the sequencing run I, while
85344522 barcoded sequences were obtained in the
sequencing run II. 71.3% and 70.4% of the obtained bar-
coded sequences were mapped to the 4 F-barcodes used
in the libraries generation, respectively. And 89.7% and
91.4% of the F-barcode mappable sequences were
mapped to the 8 R-barcodes introduced in the PCR
reactions, separately. In total, 64.0% and 64.4% of the
obtained sequences were mapped to a used F-barcodes
and a used R-barcodes at the same time. The reads
mapped to each combination of F-barcodes and R-bar-
codes are counted and exhibited in Table 1.
Mapping results
Composition of each library was determined by filtering
all decoded reads to human genome. MiRNAs were
identified by mapping reads to pre-miRNAs in miRBase
and quantified by mapping reads to mature miRNA in
miRBase. About 46% of the decoded sequences were
mappable using SOLiD system small RNA analysis pipe-
line tool (RNA2MAP, version 0.5.0) (Additional file 1).
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Page 2 of 9Unmappable sequences were neither other non-coding
human RNAs, nor fragment of human genome, as they
passed the filtering of other non-coding human RNAs
and did not map to the human genome.
After adaptor and barcode sequence removal, read
length distribution of the reads mapping to the miRBase
revealed a peak at 21-22nt (Figure 2B, Additional file 2),
indicating that mature miRNAs were enriched in the
sequenced samples. In order to evaluate the consistency
of the miRNA expression values of the two independent
runs, the raw expression values of miRNA were com-
pared in on logarithmic coordinate. Scatter plots of each
sample revealed a well reproduction quality in miRNA
expression, especially in the miRNAs whose expression
values (read counts) over 5 (Additional file 3). The
expression values were calculated by counting the reads
which mapped to the mature miRNAs in miRBase. On
average, about 15.3% (range 6.1%-38.6%) of all decoded
reads were identified as non-coding RNA. MiRNA was
the major constituent among the non-coding RNA, ran-
ged from 10% to 85%, and tRNA was the other major
non-coding RNA species (Figure 2C, Additional file 1).
The proportion of decoded reads mapped to other non-
coding RNA, miRNA, and genome was different across
the datasets (Additional file 1). No significant variation
of miRNA proportion between breast cancerous tissue
datasets and breast noncancerous tissue datasets was
detected.
Correlation of miRNA read counts without barcode to
miRNA read counts with different barcode pairs
To validate sequencing data with pair-barcode sequen-
cing approach, we examined the correlation of raw read
counts between dataset without barcode and datasets
with 16 different barcode pairs. The miRNAs whose raw
read counts were > 5 in both datasets for comparison
were selected to calculate the Pearson’s correlation coef-
ficient. Expression of most miRNAs was highly corre-
lated between the technical replicates. Comparing with
the results without barcode, the Pearson’sc o r r e l a t i o n
coefficients ranged from 0.76 to 0.92 for each barcode
pair (Figure 2A, Additional file 4). We conclude that
raw read counts obtained from pair-barcode sequencing
are valid and strong correlation to results obtained with-
out barcode.
High expressed miRNAs
We first analyzed the high expressed miRNAs both in
BC datasets and BO datasets. The miRNAs whose nor-
malized expression value over 100 in at least 20 datasets
Figure 1 Outline of PBS. A. Ligations. F-adaptors with F-barcodes at 5’ end and R-adaptors are ligated to the miRNAs consequently. B.
Reverse transcription. Reverse transcription is carried out by RT-primer to form DNA stand. C. Library amplification. The libraries were
amplified by F-primers and R-primers. The R-barcodes are located in the overhangs at 5’ end of R-primers, and the right ePCR primers are
devised at the 5’ end of R-primers. D. ePCR. The ePCR reactions are operated to transfer the libraries to magnetic beads. E. Sequencing. The
libraries are sequenced by sequencing primer A and sequencing primer B. The sequencing primer A is in charge of sequencing miRNAs and the
F-barcodes while the sequencing primer B is responsible for sequencing R-barcodes.
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were shown in Additional file 5 Table S5 (Additional file
6 Additional file 5). These criteria were met by 85 miR-
NAs, including 5 miRNA-3p sequences and 6 miRNA-
5p sequences. But no miRNA* met these criteria. The
10 most abundantly expressed miRNAs in both kinds of
datasets are exhibited in Table 2. The average of BC
was divided by the average of BO and the quotient was
taken the logarithm to calculate the ratio, based on 2.
Three of these 10 miRNAs, miR-21, let-7b, and miR-
19b, expressed differently between BC datasets and BO
datasets (ratio<-1 or ratio > 1).
Analysis of known breast cancer related miRNAs
We also analyzed miRNAs previously reported to be
differentially expressed in BC, including oncogenic
miRNAs, miR-155[17], miR-21[18,19], miR-25[30], and
miR-27a[24], and tumor suppressor miRNAs, miR-125a/
b[17], miR-17[26], miR-205[25], miR-27b[24], miR-31
[27], and miR-34a[28,29]. The expression values of these
miRNAs between BC datasets and BO datasets were
compared in logarithmic coordinates (Figure 3A). NGS
using pair-barcode revealed that the oncogenic miRNA
of miR-155 which were previously shown to be upregu-
lated in tumors [17-19], were also upregulated in BC
datasets comparing to the BO datasets. The tumor sup-
pressor miRNA of miR-31 were downregulated in BC
datasets comparing to the BO datasets [27]. The other
breast cancer associated miRNAs did not exhibit signifi-
cant difference between BC datasets and BO datasets in
our study.
MiRNAs differentially expressed between two clinical
groups
We aimed to identify other miRNAs differentially
expressed in BC datasets versus BO datasets using pair-
b a r c o d eN G S .O n l ym a t u r em i R N A sr e p r e s e n t e db y
more than 5 raw counts in at least 20 datasets of all 25
datasets were considered. 200 miRNAs met these cri-
teria, including 18 star miRNA, 20 miRNA-3p and 20
miRNA-5p sequences. A total of 22 miRNAs were dif-
ferentially expressed based on a t-test (Additional file 7),
including 1 miRNA*, 3 miRNA-3p and 1 miRNA-5p
sequences. Figure 2B exhibits the top 10 differentially
expressed miRNAs, including miRNAs previously asso-
ciated with BC, miR-31.
Discussion
PBS allows for sequencing large-scale multiplexed sam-
ples using SOLiD system and any other NGS platforms.
Comparing to the physical segregation of the sequencing
plate, PBS permits to parallel sequencing much larger
amount of samples. In some NGS platforms, physical
segregation lessens the available throughput by obscur-
ing available sequencing space. The lessening of
throughput is also found in PBS approach because the
barcodes shortens the available read length. But for
some studies, such as miRNA expression studies, the
read count is more significant than the read length
when the read length scarified the requirements of these
studies. The read length after removing 6nt F-barcodes
is 29nt in our study, which is longer than most mature
miRNAs. Furthermore, the available read length of the
latest NGS platforms are longer than the SOLiD V2 sys-
tem, 75nt of SOLiD 5500 × l and 100nt of Hiseq 2000.
PBS is more economic and efficient than the physical
segregation in these applications. In the existing single
barcode method which allows parallel analysis infinite
samples in theory like PBS, the number of tagged oligos
required is equal to the number of the samples pooled
together. If the number of pooled samples is large, the
Table 1 Decoded read counts and raw miRNA expression
values
Barcode pair/dataset Pilot run I Pilot run II
A1 1350957 1248344
A2 839729 812507
A3 654378 632717
A4 1558780 1516755
A5 1106683 1059838
A6 1083017 1086001
A7 2413058 2464352
A8 3449159 3397171
B1 743743 679503
B2 236758 225889
B3 172964 163368
B4 236646 231825
B5 585148 555769
B6 1315460 1276797
B7 710279 711801
B8 1633113 1565130
C1 12646912 11782099
C2 2708545 2635196
C3 1623237 1556327
C4 1537402 1521985
C5 928983 879860
C6 721715 742206
C7 2326266 2372511
C8 2721671 2651552
D1 1536539 1381501
D2 432199 403448
D3 2670887 2529404
D4 2770368 2662417
D5 482720 453340
D6 1750057 1707542
D7 1193768 1201293
D8 2552421 2464702
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barcode method lost its practicability. PBS approach is
considered to be an ideal method to overcome this pro-
blem. The latest sequencers generate up to 1 billion
reads, which is adequate to parallel analysis up to 100
miRNA samples. To parallel analyze 100 miRNA sam-
ples, single barcode method requires 100 barcoded oli-
gos (Table 3). By combining with physical segregation,
at least 13 barcoded oligos are remaining required.
However, totally 20 barcoded oligos are necessary by
PBS without the help of physical segregation. The
throughput of NGS has increased for dozens of times in
the past several years and continuously increases in a
rapid speed. The superior of PBS will be more signifi-
cant when the throughput becomes larger. For example,
if the researchers want to parallel analyze 10,000 sam-
ples in the future, 10,000 kinds of sample-specific pri-
mers or adaptors are needed by the existing single
Figure 2 NGS of the small RNA transcriptome. A1. Scatter plots of raw miRNA expression values of the same sample with the worst
correlation. The x-axis was determined without barcode and the y-axis determined with barcode pair A4. A2. Scatter plots of raw miRNA
expression values of the same sample with the best correlation. The x-axis was determined without barcode and the y-axis determined with
barcode pair C3. Raw expression values of miRNAs determined with 16 kinds of barcode pairs were compared with raw expression values of
miRNAs without barcode one by one, and the scatter plots are exhibited in Additional file 4. B. Read length distribution (nt) of known miRNAs
by removing adaptors and barcodes. The y-axis depicts the percentage of read lengths relative to the total number of reads in all datasets. Read
length distributions of each patient are shown in Additional file 2. C. Distribution of non-coding RNA species in the all 32 samples.
Table 2 Highly expressed miRNAs in all datasets.
Average read counts Ratio
BC BO
miR-23a 37,714 39,969 -0.08
miR-21 20,007 6,091 1.72
miR-19b 16,705 7,368 1.18
let-7b 7,871 33,016 -2.07
miR-27a 12,514 16,534 -0.40
miR-1308 11,871 12,091 -0.03
miR-181a 10,825 8,456 0.36
miR-29a 10,558 9,074 0.22
miR-205 10,346 7,839 0.40
miR-1975 7,876 6,044 0.38
The average of BC was divided by the average of BO and the quotient was
taken the logarithm to calculate the ratio, based on 2.
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1250 kinds of barcoded oligos are still indispensible.
However, only 100 varieties F-adaptors and 100 sample-
specific R-primers are required using the PBS approach
(Table 3). Moreover, F-adaptors and R-primers are
employed in two different steps of library construction,
reducing the probability of potential mistakes made
within the library construction. Comparing to the exist-
ing single barcode method, PBS approach requires sig-
nificantly less kinds of tagged oligos, about square root
of the single barcode method. Therefore, the studies
become uncomplicated and efficient.
About 71% of the reads mapped to the sequence of
the 4 F-barcodes and about 90% of the F-barcode
decoded reads mapped to the sequence of the 8 R-bar-
codes. In each of the two decoding steps, 20% of the
reads are off-target on average (Figure 2C). The ratios
are logical comparing to other SOLiD works [14]. The
vast majority of these off-target reads did not mapped
to both of the two barcodes, indicating that they were
not caused by using a pair of barcodes instead of a sin-
gle barcode. The counts of reads mapped to the barcode
pairs are tens of times difference between each other.
The existing DNA spectrophotometers, such as Nano-
drop ND-1000 are not fit for determining samples
whose concentration smaller than 2 ng/μl directly. The
final concentration of pooled libraries used for ePCR is
50 pg/μl. The libraries were determined at high concen-
tration and were diluted to 50 pg/μl. The dilution may
be one of the reasons of read counts difference cross
datasets. Although the read counts difference induced
the difference in miRNA expression, this difference can
be resolved by read counts normalization.
The percentage of mappable reads using SOLiD system
small RNA analysis pipeline tool (RNA2MAP, version
0.5.0) is at the same level of other work [14]. The read
length distribution after mapping to the miRBase is iden-
tical with the other studies [14,31], indicating that mature
miRNAs were enriched in the sequenced samples and
were well sequenced by the PBS. Hundreds of miRNAs
discovered in the pooled samples is another support. We
found an average correlation of r = 0.999 between
miRNA expression counts in replicate experiments, indi-
cating the sequencing assay is highly reproducible.
Quantile-quantile normalization was used to normal-
ize raw read counts to remove potential bias in miRNA
expression across the datasets. The quantile-quantile
normalization has been used to normalize the raw read
counts of NGS and shown to be superior to scaling to a
given constant [14]. We first analyze the high expressed
miRNAs (Table 2). Three of these 10 miRNAs expressed
differently between BC datasets and BO datasets (ratio<-
Figure 3 Differential miRNA expression between BC and BO.
The expression value zero was set as one to be visible on
logarithmic coordinates. The normalized expression values were
used to evaluate the difference between two kinds of datasets.
Black spots refer to breast cancer cancerous tissue datasets and
black circles depict breast noncancerous tissue datasets. A.
Expression data for known breast cancer associated miRNAs. B.
Expression data for the 10 best class-separating miRNAs. Rows are
sorted according to raw p-values. These data including a previously
breast cancer associate miRNA (shown in Figure 3A) as well as
newly identified differentially expressed miRNAs.
Table 3 Comparison of the current methods versus PBS.
Samples
number
PSS
1 SBS
2 Combination of PSS
1 and SBS
2 PBS
10 Allowing up to 8
samples
10 barcoded oligos 4 segments with 3 barcoded oligos 7 barcoded oligos
(4 F-barcodes and 3 R-barcodes)
100 N/A 100 barcoded oligos 8 segments with 13 barcoded oligos 20 barcoded oligos
(10 F-barcodes and 10 R-barcodes)
1000 N/A 1000 barcoded oligos 8 segments with 125 barcoded oligos 67 barcoded oligos
(34 F-barcodes and 33 R-barcodes)
10000 N/A 10000 barcoded
oligos
8 segments with 1250 barcoded
oligos
200 barcoded oligos
(100 F-barcodes and 100 R-
barcodes)
1 PSS, Physical Space segregation
2 SBS, Single barcode sequencing
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NAs, is a well known oncogene that expected to be
abundant in breast tumor [18,19]. miR-19b, the other
upregulated miRNA, is reported to be high expressed in
invasive breast cell lines versus less invasive breast cell
lines[23]. The downregulated miRNA, let-7b, is a mem-
ber of let-7 family which considered to be tumor sup-
pressor miRNAs [20].
We then analyzed miRNAs that previously associate to
breast cancer. MiR-155, which was discovered to be
upregulated in breast cancer [17-19], is also significant
upregulation in BC datasets, suggesting that it may play
as an oncogene in breast cancer. MiR-31, which is
expressed in normal breast cells and was recently shown
to prevent metastasis at multiple steps by inhibiting the
expression of prometastatic genes [27], was observed to
be downregulated in BC datasets. No significant differ-
ence between BC and BO datasets was observed in the
other 9 breast cancer associate miRNAs.
We also analyzed other miRNAs differentially
expressed between BC and BO datasets in this work. Of
all the 200 miRNAs considered, 22 miRNAs were differ-
entially expressed according to the p-values. We com-
pared the expression patterns of the 10 differentially
expressed miRNAs with published results (Figure 3B).
MiR-31, downregulated in BC datasets, was reported to
be a suppressor of breast cancer. MiR-21* was upregu-
lated in BC datasets and the non star form of miR-21*
was recognized as a breast cancer oncogenic miRNAs
[18,19]. As a member of let-7 family, a well known
breast cancer suppressor, let-7b was observed to be
downregulated in BC datasets in our study. Several miR-
NAs among the 10 most differentially expressed miR-
NAs were associated other malignancies in published
studies, including miR-15b[32,33], miR-101[34], miR-
374a[35], and miR-218[36]. The expression patterns of
these 4 miRNAs in our study are all in accord with the
work of profession. This accordance strengthens that
these 4 miRNAs are breast cancer concerning miRNAs.
We here report that miR-15b, miR-101, miR-374a and
miR-218 are breast cancer associated miRNAs by the
sequencing results of our PBS approach. For the rest 3
miRNAs, miR-487b, miR-744 and miR-2110, no paper
was found to report any relationship with malignancies.
We notice that all these 3 miRNAs have low read
counts in the two divergent clinical groups, indicating
low expression values in tissues. It may be the reason
why the different expression patterns of these miRNAs
were not reported in previous works.
Conclusions
In summary, we have developed an ideal system that
allows for high-throughput sequencing of large-scale
multiplexed samples using SOLiD system. Substantially,
comparing to the existing barcode sequencing, the sup-
posed technique improves the practicability when the
amount of samples is large. The application demon-
strates that PBS is a valid tool to discover miRNAs in
large-scale multiplexed samples. PBS approach can be
readily adapted to any existing NGS platform and will
be more widely applied along with the increasing of
NGS throughput in the next several years.
Methods
Sample preparation and RNA isolation
All participants provided written informed consent, and
the study received ethical approval from the ethics com-
mittee of the State Key Laboratory of Bioelectronics. 32
samples were derived from 26 human breast cancer can-
cerous tissues (M1-M26) and 6 human breast noncan-
cerous tissues (C1-C6) and kept in TRIzol (Qiagen Inc.,
Shanghai, China) before RNA isolation. MiRNAs were
extracted from each sample using mirVana miRNA iso-
lation kit (Ambion Inc., Austin, TX, USA). MiRNA
quantity and quality were checked by spectrophot-
ometer, Nanodrop ND-1000 (Thermo Fisher Scientific
Inc., Waltham, MA, USA). The clinical data of patients
are shown in Additional file 8.
Small RNA library generation and sequencing
F-adaptors and R-adaptors were ligated to miRNA sam-
ples consequently with a size-selection by polyacryla-
mide gel electrophoresis to purify the library after each
ligation. Each F-adaptor contains a unique F-barcode for
6-nt in length. The RT-primers were added to carry out
reverse transcription. The libraries were then amplified
by PCR reactions, in which the R-barcodes for 6-nt in
length were introduced by the R-primers. One more
size-selection by polyacrylamide gel electrophoresis was
done after the PCR reactions. The 32 samples were
mixed in a pool at the same concentration to operate
emulsion PCR (ePCR). Template bead preparation,
ePCR and deposition were performed according to the
standard protocol, and slides were analyzed on a SOLiD
system V2 (Applied Biosystems Inc., Foster City, CA,
USA) according to the multiplexing protocol. The
sequences of oligos used in this paper are shown in
Additional file 9. Sample M-14 was selected to perform
technical replicates with different barcodes. This sample
was sequenced directly without barcode, and with 16
barcode pairs.
Decoding, mapping and data analysis
SOLiD reads were decoded by the F-barcodes and R-
barcodes consequently allowing one mismatch in each
6nt coding region. The reads which match an F-barcode
and an R-barcode uniquely and simultaneously were
used for mapping (Additional file 9). Mapping of SOLiD
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analysis pipeline tool (RNA2MAP, version 0.5.0). After
filtering the other human non-coding RNAs, raw
expression values (read counts) were obtained by sum-
ming the number of reads that mapped uniquely to the
reference database, miRBase release 14.0 and Human
Genome RefSeq Hg19. We allowed two mismatches for
the first 18nt and three mismatches for the remaining
11nt of each decoded reads (Additional file 6).
Normalization of read counts
In order to quantify and compare miRNA expression
across datasets, raw read counts were normalized using
quantile-quantile normalization to remove a potential
bias. Dataset M1 was chosen as a reference, and the
scaling factors were obtained by computing the median
of differences of corresponding quantile values of a data-
set and the reference dataset. The distribution of abso-
lute count values > 5 both in the dataset and the
reference dataset were compared in logarithmic space.
All datasets were normalized by linear transformations
using the scaling factors (Additional file 6) [14].
Additional material
Additional file 1: Statistics after mapping. Statistics after mapping
decoded NGS reads to the other non coding RNAs, Human Genome
(RefSeq Hg19) and miRBase (Release 14.0).
Additional file 2: MiRNA read length distribution. Exhibit the miRNA
read length distribution of each patient.
Additional file 3: MiRNA read counts of two independent runs.
Scatter plots of miRNA expressions of all 32 barcode pairs of two
independent runs.
Additional file 4: MiRNA read counts of different barcode pairs.
Scatter plots of miRNA read counts of the same sample without barcode
to with different barcode pairs.
Additional file 5: Highly expressed miRNAs. Highly expressed miRNAs
in all 25 datasets.
Additional file 6: Mapping and normalization. The detailed
progression of mapping and normalization.
Additional file 7: Different expressed miRNAs. The 22 miRNAs which
were differentially expressed between breast malignant and breast
carcinoid based on a t-test.
Additional file 8: Clinical data. Clinical data of the patients included in
this study.
Additional file 9: Encoding and decoding. Details of the encoding and
decoding progress.
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